Asia Pacific Mid-Size Pharmaceutical Market Forecast to 2028

Report Code : BMIRE00026172 | Region : Asia Pacific | Industry : Pharmaceuticals | Published Date : 22/Sep/2022
Asia Pacific Mid-Size Pharmaceutical Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Prescription and Over-the-Counter), Drug Development Type (In-House and Outsource), Formulation (Tablets and Capsules, Injectables, Sprays, and Other Formulations), and Therapy Class (Cardiovascular Diseases, Pain Management, Diabetes, Cancer, and Other Conditions)

The mid-size pharmaceutical market in Asia Pacific is expected to grow from US$ 131,119.99 million in 2022 to US$ 196,114.51 million by 2028; it is estimated to grow at a CAGR of 6.9% from 2022 to 2028.

Over the last decade, the pharmaceutical industry has witnessed many transformational trends and innovations that will improve the medicines available to patients around the region. In just ten years, the influence of artificial intelligence and big data on diagnosing and treating diseases and a shift toward preventing life-threatening conditions rather than medicating them lead to evolution of healthcare. With the evolution of recent technologies, new entrants initiate several health start-ups. For instance, Christopher Benoit, an expert in enzyme development and production, founded Alpha zyme in 2018. In October 2020, Alp zyme partnered with Qualio to facilitate the company’s growth.

Unlike large pharmaceutical companies, medium-sized pharmaceutical companies are usually not constrained by huge overheads and bureaucracy. However, these companies have focus on specific areas of drug development. In recent years, partnerships between the pharmaceutical and digital health companies have increased significantly. These commercial deployment deals are aimed at digitally-enabled pharmaceutical products, creating new companies, or multibillion-dollar acquisitions. Thus, pharma companies are a growing part of the digital health boom. Therefore, the rising number of healthcare start-ups is expected to offer lucrative growth opportunities for the growth of the Asia Pacific mid-size pharmaceutical market in the coming years.

By introducing new features and technologies, vendors in the Asia Pacific mid-size pharmaceutical market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market growth at a good CAGR during the forecast period.

Asia Pacific Mid-Size Pharmaceutical Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Mid-Size Pharmaceutical Market Segmentation

The Asia Pacific mid-size pharmaceutical market is segmented on the basis of type, drug development type, formulation, therapy class, and country.

Based on type, the Asia Pacific mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share. Based on drug development type, the market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022. Based on formulation, the Asia Pacific mid-size pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022. Based on therapy class, the market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022. Based on country, the Asia Pacific mid-size pharmaceutical market is segmented into Australia, China, India, Japan, South Korea, and Rest of Asia Pacific. China held the largest market share in 2022.

Alexion Pharmaceuticals, Inc.; Bausch Health Companies Inc.; Daiichi Sankyo Company Limited; Eisai Co., Ltd.; Endo Pharmaceuticals Inc.; Mallinckrodt; Regeneron Pharmaceuticals, Inc; and Sun Pharmaceutical Industries Ltd are among the leading companies operating in the mid-size pharmaceutical market in the region.

The List of Companies - Asia Pacific Mid-Size Pharmaceutical Market

● Alexion Pharmaceuticals, Inc.

● Bausch Health Companies Inc.

● Daiichi Sankyo Company Limited

● Eisai Co., Ltd.

● Endo Pharmaceuticals Inc.

● Mallinckrodt

● Regeneron Pharmaceuticals, Inc

● Sun Pharmaceutical Industries Ltd

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 APAC Mid-Size Pharmaceutical – By Type

1.3.2 APAC Mid-Size Pharmaceutical – By Drug Development Type

1.3.3 APAC Mid-Size Pharmaceutical – By Formulation

1.3.4 APAC Mid-Size Pharmaceutical – By Therapy Area

1.3.5 APAC Mid-Size Pharmaceutical – By Country

2. Mid-Size Pharmaceutical– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. APAC Mid-Size Pharmaceutical – Market Landscape

4.1 Overview

4.2 APAC PEST Analysis

4.3 Expert Opinion

5. Mid-Size Pharmaceutical Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Chronic Disorders

5.1.2 Increasing Product Approval and Launches

5.2 Market Restraints

5.2.1 High Competition Among Market Players

5.3 Market Opportunities

5.3.1 Rising Number of Healthcare Start-ups

5.4 Future Trends

5.4.1 Increasing Focus on R&D

5.5 Impact Analysis

6. Mid-Size Pharmaceutical Market– APAC Analysis

6.1 APAC Mid-Size Pharmaceutical Market Revenue Forecast And Analysis

7. APAC Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028– by Type

7.1 Overview

7.2 APAC Mid-Size Pharmaceutical Market Revenue Share, by Type (2022 and 2028)

7.3 Prescription

7.3.1 Overview

7.3.2 Prescription: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Over-the-Counter (OTC)

7.4.1 Overview

7.4.2 Over-the-Counter: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

8. APAC Mid-Size Pharmaceutical Market Analysis – By Drug Development Type

8.1 Overview

8.2 APAC Mid-Size Pharmaceutical Market Revenue Share, by Drug Development Type (2022 and 2028)

8.3 In-House

8.3.1 Overview

8.3.2 In-House: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Outsource

8.4.1 Overview

8.4.2 Outsource: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9. APAC Mid-Size Pharmaceutical Market – By Formulation

9.1 Overview

9.2 APAC Mid-Size Pharmaceutical Market, by Formulation, 2022 and 2028 (%)

9.3 Tablets and Capsules

9.3.1 Overview

9.3.2 Tablets and Capsules: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Injectables

9.4.1 Overview

9.4.2 Injectables: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9.5 Sprays

9.5.1 Overview

9.5.2 Sprays: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Other Formulations

9.6.1 Overview

9.6.2 Others: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10. APAC Mid-Size Pharmaceutical Market – By Therapy Class

10.1 Overview

10.2 APAC Mid-Size Pharmaceutical Market, by Therapy Class, 2022 and 2028 (%)

10.3 Cardiovascular Diseases

10.3.1 Overview

10.3.2 Cardiovascular Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Pain Management

10.4.1 Overview

10.4.2 Pain Management: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.5 Diabetes

10.5.1 Overview

10.5.2 Diabetes: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.6 Cancer

10.6.1 Overview

10.6.2 Cancer: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.7 Other Diseases

10.7.1 Overview

10.7.2 Other Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11. APAC Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 – Country Analysis

11.1 Overview

11.1.1 APAC: Mid-Size Pharmaceutical Market, by Country, 2022 & 2028 (%)

11.1.1.1 China: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.1.1 China: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.1.2 China: Mid-Size Pharmaceutical Market, By Type, 2019–2028 (USD Million)

11.1.1.1.3 China: Mid-Size Pharmaceutical Market, By Drug Development Type, 2019–2028 (USD Million)

11.1.1.1.4 China: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)

11.1.1.1.5 China: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)

11.1.1.2 Japan: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.2.1 Japan: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.2.2 Japan: Mid-Size Pharmaceutical Market, By Type, 2019–2028 (USD Million)

11.1.1.2.3 Japan: Mid-Size Pharmaceutical Market, By Drug Development Type , 2019–2028 (USD Million)

11.1.1.2.4 Japan: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)

11.1.1.2.5 Japan: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)

11.1.1.3 India: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.3.1 India: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.3.2 India: Mid-Size Pharmaceutical Market, By Type , 2019–2028 (USD Million)

11.1.1.3.3 India: Mid-Size Pharmaceutical Market, By Drug Development Type, 2019–2028 (USD Million)

11.1.1.3.4 India: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)

11.1.1.3.5 India: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)

11.1.1.4 Australia: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.4.1 Australia: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.4.2 Australia: Mid-Size Pharmaceutical Market , By Type , 2019–2028 (USD Million)

11.1.1.4.3 Australia: Mid-Size Pharmaceutical Market , By Drug Development Type , 2019–2028 (USD Million)

11.1.1.4.4 Australia: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)

11.1.1.4.5 Australia: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)

11.1.1.5 South Korea: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.5.1 South Korea: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.5.2 South Korea: Mid-Size Pharmaceutical Market, By Type, 2019–2028 (USD Million)

11.1.1.5.3 South Korea: Mid-Size Pharmaceutical Market, By Drug Development Type , 2019–2028 (USD Million)

11.1.1.5.4 South Korea: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)

11.1.1.5.5 South Korea: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)

11.1.1.6 Rest of APAC: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.6.1 Rest of APAC: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (USD Million)

11.1.1.6.2 Rest of APAC: Mid-Size Pharmaceutical Market, By Type, 2019–2028 (USD Million)

11.1.1.6.3 Rest of APAC: Mid-Size Pharmaceutical Market, By Drug Development Type, 2019–2028 (USD Million)

11.1.1.6.4 Rest of APAC: Mid-Size Pharmaceutical Market, By Formulation, 2019–2028 (USD Million)

11.1.1.6.5 Rest of APAC: Mid-Size Pharmaceutical Market, By Therapy Area, 2019–2028 (USD Million)

12. Mid-Size Pharmaceutical Market–Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 DAIICHI SANKYO COMPANY LIMITED

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Eisai Co., Ltd.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Bausch Health Companies Inc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Regeneron Pharmaceuticals, Inc

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Sun Pharmaceutical Industries Ltd

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Alexion Pharmaceuticals, Inc.

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Mallinckrodt

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Endo Pharmaceuticals Inc.

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1.             China: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 2.             China: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and forecast to 2028 (USD Million)

Table 3.             China: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)

Table 4.             China: Mid-Size Pharmaceutical Market , By Therapy Area– Revenue and Forecast to 2028 (USD Million)

Table 5.             Japan: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 6.             Japan: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)

Table 7.             Japan: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)

Table 8.             Japan: Mid-Size Pharmaceutical Market , By Therapy Area– Revenue and Forecast to 2028 (USD Million)

Table 9.             India: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 10.          India: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)

Table 11.          India: Mid-Size Pharmaceutical Market, By Formulation - Revenue and Forecast to 2028 (USD Million)

Table 12.          India: Mid-Size Pharmaceutical Market, By Therapy Area– Revenue and Forecast to 2028 (USD Million)

Table 13.          Australia: Mid-Size Pharmaceutical Market , By Type – Revenue and Forecast to 2028 (USD Million)

Table 14.          Australia: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)

Table 15.          Australia: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)

Table 16.          Australia: Mid-Size Pharmaceutical Market, By Therapy Area – Revenue and Forecast to 2028 (USD Million)

Table 17.          South Korea: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 18.          South Korea: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)

Table 19.          South Korea: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)

Table 20.          South Korea: Mid-Size Pharmaceutical Market, By Therapy Area – Revenue and Forecast to 2028 (USD Million)

Table 21.          Rest of APAC: Mid-Size Pharmaceutical Market, By Type – Revenue and Forecast to 2028 (USD Million)

Table 22.          Rest of APAC: Mid-Size Pharmaceutical Market, By Drug Development Type – Revenue and Forecast to 2028 (USD Million)

Table 23.          Rest of APAC: Mid-Size Pharmaceutical Market, By Formulation – Revenue and Forecast to 2028 (USD Million)

Table 24.          Rest of APAC: Mid-Size Pharmaceutical Market, By Therapy Area – Revenue and Forecast to 2028 (USD Million)

Table 25.          Organic Developments Done By Companies

Table 26.          Inorganic Developments Done By Companies

Table 27.          Glossary of Terms

The List of Companies - Asia Pacific Mid-Size Pharmaceutical Market

● Alexion Pharmaceuticals, Inc.

● Bausch Health Companies Inc.

● Daiichi Sankyo Company Limited

● Eisai Co., Ltd.

● Endo Pharmaceuticals Inc.

● Mallinckrodt

● Regeneron Pharmaceuticals, Inc

● Sun Pharmaceutical Industries Ltd

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific mid-size pharmaceutical market

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific mid-size pharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the mid-size pharmaceutical market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Asia Pacific Mid-Size Pharmaceutical Market Forecast to 2028)
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry